|Bid||1.03 x 900|
|Ask||1.08 x 3000|
|Day's Range||1.0600 - 1.0900|
|52 Week Range||0.9000 - 2.0900|
|Beta (3Y Monthly)||1.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 6, 2019 - Feb 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||2.60|
NEW YORK, Feb. 12, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Organovo (ONVO) delivered earnings and revenue surprises of 14.29% and -10.15%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 6 cents. The results surpassed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
Pre-Investigational New Drug (“IND”) meeting with the FDA expected to be held in calendar 2019Submit first IND in calendar 2020 SAN DIEGO, Feb. 07, 2019 -- Organovo Holdings,.
Organovo (ONVO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
A look at the shareholders of Organovo Holdings, Inc. (NASDAQ:ONVO) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual Read More...
SAN DIEGO, Jan. 17, 2019 -- Organovo Holdings, Inc. (NASDAQ:ONVO) (“Organovo”) will host a conference call on Thursday, February 7, 2019 at 5:00 p.m. Eastern Time (ET) to.
Organovo Holdings, Inc. (ONVO) (“Organovo”), a biotechnology company pioneering the development of 3D bioprinted tissues aimed at treating a range of serious adult and pediatric liver diseases, today announced that its board of directors has appointed one new member. David Shapiro, M.D., Chief Medical Officer of Intercept Pharmaceuticals, Inc. (“Intercept”), will join Organovo’s board, effective immediately. Dr. Shapiro’s appointment increases the number of Organovo directors to eight.
Organovo (ONVO) delivered earnings and revenue surprises of 37.50% and 4.43%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the San Diego-based company said it had a loss of 5 cents. The development-stage company focused on commercializing functional human tissue for drug and biological research posted ...
On Thursday, Nov. 8, Organovo Holdings (NYSE: ONVO ) will release its latest earnings report. Check out Benzinga's report to understand the earnings report's implications. Earnings and Revenue Wall Street ...
The direct benefit for Organovo Holdings Inc (NASDAQ:ONVO), which sports a zero-debt capital structure, to include debt in its capital structure is the reduced cost of capital. However, the trade-offRead More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 9) Acer Therapeutics Inc (NASDAQ: ACER )(HC Wainwright reiterated ...